Business Wire

TX-MARY-KAY

Share
Mary Kay Inc. Celebrates International Day of Forests and World Tree Day with Report Detailing Impactful Partnership with the Arbor Day Foundation

Good things come in trees. Following International Day of Forests and World Tree Day, Mary Kay Inc. , a global leader in corporate stewardship and sustainability, is releasing a report detailing its long-standing partnership with the Arbor Day Foundation . Together, Mary Kay Inc. and the Arbor Day Foundation have planted over 1.2 million trees across the globe, making a measurable impact on climate change, CO2 emissions, and reforestation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220321005134/en/

“Globally, around 18 million acres of trees are lost each year,” said Deborah Gibbins , Chief Operating Officer at Mary Kay Inc. “To raging wildfires, insects, disease, climate change, and more, the need for reforestation is dire. Mary Kay has a footprint in markets around the world—so we must do what we can to protect it. Our partnership with the Arbor Day Foundation allows us to provide a more sustainable future for generations to come.”

Mary Kay’s latest trees report, which can be found linked below on MaryKayGlobal.com, details three cumulative benefits to planting trees through the work the partnership has completed so far.

  • Carbon: Planting, protecting, and managing trees absorbs carbon. As trees grow, carbon is removed from the atmosphere into trunks, roots, and branches.
    • Metric Tons of CO2 Sequestered to Date: 1,018,021
  • Water: Trees and forests play a vital role in water quality and quantity. Healthy trees and forests reduce soil erosion, filter stormwater and agricultural irrigation, enhance rainfall infiltration, and reduce surface runoff
    • Gallons Avoided Water Runoff: 81,902,445 (equal to 930,710 people with clean water)
  • Air: Trees produce oxygen that we breathe. In addition, trees remove air pollution by lowering air temperature, by releasing water into the atmosphere, and by filtering particulates.
    • Tons of Air Pollutants Removed: 4,236

In 2021, Mary Kay Inc. completed six main planting projects in partnership with the Arbor Day Foundation. These included:

  • 7,000 trees in Brazil’s Indigenous Fire Recovery Project
  • 26,496 trees in the Mississippi River Valley
  • 49,004 trees in Florida’s Tyndall Air Force Base
  • 7,500 trees in China’s Gansu Province and Inner Mongolia Forests
  • 5,000 trees in Cajamarca and Amazonia, Peru
  • 5,000 trees in Germany’s Insect Restoration Forests.

In 2022, Mary Kay plans to plant in China, Brazil, Madagascar, and Florida.

In addition to their partnership with the Arbor Day Foundation, Mary Kay served as the executive producer for Forest of Hope , a documentary journey that highlights the battle to save our planet from the impending threats of climate change and destructive human behavior. In partnership with Media One and the Nature Conversancy, Mary Kay visited Monterrey, Mexico, to shed light on a group of female entrepreneurs who are focused on restoring a local species of trees and ecosystems. The film debuted in 2021 and is scheduled to show at upcoming film festivals.

To view the full Mary Kay Inc. / Arbor Day Foundation report, click here .

About Mary Kay Inc.

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com , find us on Facebook , Instagram , and LinkedIn or follow us on Twitter .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye